Abstract
Neuroinflammation plays a key role in progressive degeneration of dopaminergic cells. Upregulation of prostaglandins and free radicals formation are involved in the mechanisms of cell death in Parkinson’s disease (PD). The present study aimed to investigate the neuroprotective effect of diclofenac against chlorpromazine (CPZ) induced catalepsy and motor impairment in mice. Adult Wistar rats treated with CPZ (3 mg/kg/day, IP) were orally dosed with diclofenac and L-dopa/carbidopa for 21 days. Catalepsy was measured after 21 days of dosing by using standard bar test at 30, 60, 90, 120 and 180 min then motor performances were assessed via open field test and wire hanging test. Histopathological investigation and determination of dopamine (DA) and 3,4-Dihydroxyphenylacetic acid (DOPAC) levels of rat’s brain was also carried out. We found that CPZ treated group exhibited reduced motor impairment after 21 days of treatment in open field and wire hanging test (P < 0.01) as compared to control group. The cataleptic scores of CPZ treated rats were also significantly increased (P < 0.01) after 21 days of chronic dosing, however diclofenac treated groups showed significant reduction in cataleptic scores with improved motor performances. Histopathology of CPZ treated rats showed marked degeneration with architecture distortion in the mid brain region. Dopaminergic degeneration is confirmed by neurochemical results that showed reduced amount of dopamine and DOPAC levels in mid brain. Moreover, histopathological slides of diclofenac treated rats showed improved architecture with reduced gliosis of mid brain region as well as improved dopamine and DOPAC levels were achieved after 21 days dosing of diclofenac. Taken together, the present work provide an evidence that diclofenac ameliorated behavioral performances by mediating neuroprotection against CPZ induced PD via preventing dopaminergic neuronal cell death.
Similar content being viewed by others
References
Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33:430.e1–430.e3
Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 3(6):1949–1964
Al-Amin MM, Uddin MM, Rahman MM, Reza HM, Rana MS (2013) Effect of diclofenac and antidepressants on the inflammatory response in astrocyte cell culture. Inflammopharmacology 21(6):421–425
Asanuma M, Miyazaki I, Kohno M, Ogawa N (2001) Neuroprotective effects on non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 76:1895–1904
Bendlin BB, Newman LM, Ries ML, Puglielli L, Carlsson CM, Sager MA, Johnson SC (2010) NSAIDs may protect against age-related brain atrophy. Front Aging Neurosci 2:35
Bigoniya P, Rana AC (2005) Psychopharmacological profile of hydro-alcoholic extract of euphorbia Neriifolia leaves in mice and rats. Indian J Exp Biol 43:859–862
Bishnoi M, Chopra K, Kulkarni SK (2006) Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552(1–3):55–66
Bonetto A, Andersson DC, Waning DL (2015) Assessment of muscle mass and strength in mice. Bonekey Rep 4:732
Cairo TA, Woodward TS, Ngan ET (2006) (2006). Decreased encoding efficiency in schizophrenia. Biol Psychiatry 59:740–746
Carta AR, Pisanu A (2013) Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotox Res 23(2):112–123
Casper D, Yaparpalvi U, Rempel N, Werner P (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 289:201–20410
Chen T, Koga K, Li XY, Zhuo M (2010) Spinal microglial motility is independent of neuronal activity and plasticity in adult mice. Mol Pain 6:19
Choi SH, Aid S, Bosetti F (2009) The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 30:174–181
Choi S-H, Aid S, Caracciolo L, Sakura Minami S, Niikura T, Matsuoka Y, Turner RS, Mattson MP, Bosetti F (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem 124(1):59–68
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558–567
Conner EM, Grisham MB (1996) Inflammation, free radicals an antioxidants. Nutrition 12:274–277
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909
De La Garza R, Asnis GM (2003). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus Brain Res 4;977(1):70-9
De La Garza R, Fabrizio KR, Radoi GE, Vlad T, Asnis GM (2004) (2004). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release. Behav Brain Res 149(1):77–85
De La Garza R, Asnis GM, Fabrizio KR, Pedrosa E (2005) Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats. Psychopharmacology (Berl) 179(2):356–365
Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol 2012, Article ID 645460:13
Díaz-González F, Sánchez-Madrid F (2015) NSAIDs: learning new tricks from old drugs. Eur J Immunol 45(3):679–686
Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T (2011) Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ 342:d198
Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 9:349–372
Fahn S, Przedborski S (2000) Parkinsonism. In: Rowland LP (ed) Parkinsonism in Merritt’s neurology. Lippincott, Williams & Wilkins, New York, pp 679–693
Feng Z, Li D, Fung PCW, Pei Z, Ramsden DB, Ho S (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. NeuroReport 14(15):1927–1929
Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259–272
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918–934
Griffin WS (2006) (2006). Inflammation and neurodegenerative diseases. Am J Clin Nutr 83:470–474
Guldberg HC, Yates CM (1969) Effects of chlorpromazine on the metabolism of catecholamines in dog brain. Br J Pharmacol 36(3):535–548
Hassanein NM, Hasan WA, Hamed MR (2004) (2004). Effects of diclofenac, piroxicam and alpha-tocopherol on monoaminelymphopoietic interfacing in mice. Arzneimittelforschung. 54(12):847–856
Hernandes MS, Britto LRG (2012) NADPH Oxidase and Neurodegeneration. Curr Neuropharmacol 10(4):321–327
Homykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2–S9
Hoozemans JJ, O'Banion MK (2005) The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 4:307–315
Jaturapatporn D, Isaac MG, Mc-Cleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev 2:CD006378
Kaplan AA, Yurt KK, Deniz OG, Altun G (2017) Peripheral nerve and diclofenac sodium: molecular and clinical approaches. J Chem Neuroanat 87:2–11
Karch AM (2009). Focus on nursing pharmacology, 5thed. Philadelphia: Lippincott Williams & Wilkins; publishing CO, New York, pp. 548–551
Khatoon H, Najam R, Mirza T, Sikandar B (2016) Beneficial anti-parkinson effects of camel milk in Chlorpromazine- induced animal model: Behavioural and histopathological study. Pak J Pharm Sci 29(5):1525–1529
Klockgether T (2004) Parkinson’s disease:clinical aspects. Cell Tissue Res 318:115–120
Kołaczkowski M, Mierzejewski P, Bienkowski P, Wesołowska A, Newman-Tancredi A (2014) Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. NaunynSchmiedeberg’s. Arch Pharmacol 387(6):545–557
Krause DL, Müller N (2010) Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis 2010:732806
Kulkarni SK (2007). Handbook of experimental pharmacology: 3 rd revised ed. New Delhi: VallabhPrakashan; p. 135-7
L’ Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 9:349–372
Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPAR gamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5:481–489
Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598–605
Makunts T, Cohen IV, Lee KC, Abagyan R (2018) Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. PLoS One 13(4):e0195521
Marsden CD, Calne DB (1994) Recent development in parkinson's disease. Florham Park, Macmillan; Health Care Information, pp 153–164
Milusheva E, Baranyi M, Kittel A, Fekete A, Zelles T, Vizi ES, Sperlágh B (2008) Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment. J Neurochem 105(2):360–368
Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a009381
Naeem S, Ikram R, Khan SS, Rao SS (2017) NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine. Pak J Pharm Sci 30(3):801–808
Nair V, Arjuman A, Dorababu P, Gopalakrishna HN, Rao UC, Mohan L (2007) Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. Indian J Med Res 126:480–484
Ng F, Berk M, Dean O, Bush AI (2008) 2008. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11(6):851–876
Parepally JM, Mandula H, Smith QR (2006) Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 23:873–881
Parikh V, Khan MM, Mahadik SP (2003) Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37:43–51
Pires JG, Bonikovski V, Futuro-Neto HA (2005) Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 38(12):1867–1872 Epub
Pizza V, Agresta A, D'Acunto CW, Festa M, Capasso A (2011) Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets 10(5):621–634
Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119–145
Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66–71
Riaz B, Ikram R, Sikandar B (2018 Mar) 2018. Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease. Pak J Pharm Sci 31(2):393–397
Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966(2):245–252
Sandhu K, Rana A (2013). Evaluation of antiparkinson’s activity of Nigella Sativa seeds in chlorpromazine induced experimental animal model . Academic Sciences: Aug 201, Vol 5, Suppl 3, 0975-1491
Sestakova N, Puzserova A, Kluknavsky M, Bernatova I (2013) Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip Toxicol 6(3):126–135
Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (2000) Action of adenosine A2A receptor antagonist KW-6002 on drug induced catalepsy and hypokinesia caused by reserpine. Psychopharmacology 1324
Swiatkiewicz M, Zaremba M, Joniec I, Cztonkowski A, Kurkowska-Jastrzebska I (2013) Potential neuroprotective effect of ibuprofen, insight from the mice model of Parkinson disease. Pharmacol Rep 65:1227–1236 Issue 1734-1140
Taepavarapruk P, Floresco SB, Phillips AG (2000) Hyperloco-motion and increased dopamine efflux in the rat nucleus accumbens evoked by electrical stimulation of the ventral subiculum: role of ionotropic glutamate and dopamineD1 receptors. Psychopharmacology (Berlin) 151:242–251
Takahashi E, Niimi K, Itakura C (2009) Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2.1 mutant mice. Brain Res 1279:50–57
Takween S, Ahmed SP, Haider S, Haleem DJ (1998) Effect of chlorpromazine on brain biogenic amines in normal and hyperglycemic state. Pak J Pharm Sci 11(2):23–29
Tansey MG, Goldberg MS (2009) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518
Terry AV, Warner SE, Vandenhuerk L, Pillai A, Mahadik SP, Zhang G, Bartlett MG (2008) Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 156(4):1005–1016
Terzi M, Altun G, Şen S, Kocaman A, Kaplan AA, Yurt KK, Kaplan S (2018) The use of non-steroidal anti-inflammatory drugs in neurological diseases. J Chem Neuroanat 87:12–24
Ton TG, Heckbert SR, Longstreth WT et al (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord 21:964–969
Townsend KP, Pratico D (2005) Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19:1592–1601
Wakade CG, Mahadik SP, Waller JL, Chiu FC (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69:72–79
Walker D, Lue L-F (2007) Anti-inflammatory and immune therapy for Alzheimer’s disease: current status and future directions. Curr Neuropharmacol 5(4):232–243
Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 4:19
Whitton PS (2007) Inflammation as a causative factor in the etiology of Parkinson's disease. Br J Pharmacol 150(8):963–976
Yamada T, Kawamata T, Walker DG, McGeer PL (1992) Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol 84(2):157–162
Zhang W, Wang T, Pei Z et al (2005) Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19(6):533–542
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest associated with this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Naeem, S., Najam, R., Khan, S.S. et al. Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats. Metab Brain Dis 34, 1191–1199 (2019). https://doi.org/10.1007/s11011-019-00416-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-019-00416-1